Pain Therapeutics Inc., King deal

Pfizer Inc. (NYSE:PFE, New York, N.Y.) terminated a deal to develop and commercialize Remoxy oxycodone and will return rights to the compound to Pain. Pfizer made the decision after completing an internal review of top-line data from five recently completed clinical trials required to address a 2011 complete response letter from FDA for Remoxy to treat pain. Pain plans to seek a new partner for Remoxy and said an NDA resubmission to FDA is still on track for mid-2015 (see BioCentury, Oct. 28, 2013). ...